Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.355
-0.021 (-5.53%)
At close: Dec 20, 2024, 4:00 PM
0.350
-0.005 (-1.44%)
After-hours: Dec 20, 2024, 7:57 PM EST
Oragenics Employees
Oragenics had 5 employees as of December 31, 2023. The number of employees decreased by 1 or -16.67% compared to the previous year.
Employees
5
Change (1Y)
-1
Growth (1Y)
-16.67%
Revenue / Employee
n/a
Profits / Employee
-$3,993,245
Market Cap
4.34M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Mainz Biomed | 71 |
Predictive Oncology | 35 |
Galmed Pharmaceuticals | 8 |
Autonomix Medical | 8 |
Allarity Therapeutics | 6 |
Synaptogenix | 5 |
Lixte Biotechnology Holdings | 4 |
Protagenic Therapeutics | 3 |
OGEN News
- 5 days ago - Oragenics, Inc. Announces Conversion of Preferred Shares and Elimination of Liquidation Preference - GlobeNewsWire
- 2 months ago - Oragenics, Inc. to Present at The Centurion One Capital 2nd Annual Bahamas Summit - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Updates Shareholders on Concussion Drug Progress and Phase II Trial Preparation - GlobeNewsWire
- 2 months ago - Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002 - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Announces Closing of Public Offering - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Announces Pricing of Public Offering - GlobeNewsWire
- 4 months ago - Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards - GlobeNewsWire